Free tool
FAERS Monitor: Loseasonique
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022262 or its brand name (Loseasonique, Ethinyl Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.
Reports
47
Serious
19
40% of reports
Hospitalization
6
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- condition aggravated4
- dizziness4
- drug ineffective4
- nausea4
- suicidal ideation4
- anxiety3
- depression3
- fatigue3
- tremor3
- exposure during pregnancy2
- feeling abnormal2
- headache2
- irritability2
- memory impairment2
- nasopharyngitis2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2015 | 4 |
| 2016 | 13 |
| 2017 | 6 |
| 2018 | 7 |
| 2019 | 6 |
| 2020 | 4 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,112 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| suicidal ideationSignal | 4 | 19.6 | 7.7 | 53 |
| irritability | 2 | 14.9 | 3.8 | 14 |
| exposure during pregnancy | 2 | 14.4 | 3.7 | 13 |
| tremorSignal | 3 | 8.1 | 2.7 | 12 |
| memory impairment | 2 | 6.5 | 1.7 | 5 |
| depressionSignal | 3 | 5.9 | 2.0 | 8 |
| condition aggravatedSignal | 4 | 5.9 | 2.3 | 12 |
| nasopharyngitis | 2 | 4.9 | 1.3 | 3 |
| anxietySignal | 3 | 4.7 | 1.6 | 6 |
| feeling abnormal | 2 | 3.7 | 1.0 | 2 |
| dizzinessSignal | 4 | 3.6 | 1.4 | 5 |
| nausea | 4 | 2.3 | 0.9 | 2 |
| fatigue | 3 | 1.7 | 0.6 | 0 |
| headache | 2 | 1.4 | 0.4 | 0 |
| drug ineffective | 4 | 1.4 | 0.5 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.